Hydrapres is selling at 0.42 as of the 28th of November 2024; that is 2.44 percent up since the beginning of the trading day. The stock's lowest day price was 0.42. Hydrapres has hardly any chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Hydrapres are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Although Hydrapres' alpha and beta are two of the key measurements used to evaluate Hydrapres' performance over the market, the standard measures of volatility play an important role as well.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Hydrapres stock to make a market-neutral strategy. Peer analysis of Hydrapres could also be used in its relative valuation, which is a method of valuing Hydrapres by comparing valuation metrics with similar companies.
When running Hydrapres' price analysis, check to measure Hydrapres' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hydrapres is operating at the current time. Most of Hydrapres' value examination focuses on studying past and present price action to predict the probability of Hydrapres' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hydrapres' price. Additionally, you may evaluate how the addition of Hydrapres to your portfolios can decrease your overall portfolio volatility.